Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged ≥65 years with rheumatoid arthritis

These results suggest that costs of RA-related care during the first year of therapy may be lower among RA patients aged ≥65 years receiving etanercept versus infliximab, a difference attributable primarily to lower costs of drug acquisition.